Open AccessA Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults
Author(s) -
Ruth A. Karron,
Karen Callahan,
Catherine J. Luke,
Bhagvanji Thumar,
Josephine M. McAuliffe,
Elizabeth Schappell,
Tomy Joseph,
Kathleen Coelingh,
Hong Jin,
George Kemble,
Brian R. Murphy,
Kanta Subbarao
Publication year - 2009
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/596558
Subject(s) - live attenuated influenza vaccine , medicine , virology , hemagglutination assay , pandemic , antibody , attenuated vaccine , immunology , influenza a virus subtype h5n1 , neutralizing antibody , nasal administration , vaccination , influenza vaccine , covid-19 , virus , biology , infectious disease (medical specialty) , titer , virulence , disease , biochemistry , gene
Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID(50) doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intranasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses. The vaccine was well tolerated; vaccine shedding was minimal. After 2 doses, 92% of H9-seronegative participants had > or = 4-fold increases in hemagglutination-inhibition antibody, and 79% had > or = 4-fold increases in neutralizing antibody; 100% had responses detected by at least 1 assay. Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults. Trial registration. ClinicalTrials.gov identifier: NCT00110279 .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom